International Journal of Case Studies (ISSN Online 2305-509X)

VOLUME 15, ISSUE 1
IMPACT FACTOR 4.428

1) The Association between the Use of Non-Steroidal Anti-Inflammatory Drugs And Helicobacter Pylori Infection Among Patients Attending Private Clinics In The Borama District, Somaliland
Author Details: Abdirashid S. Yusuf ^a*a, Josiah Odongo Osiri^b Sunday Adesina Adebisi ^{c a} Department of   Medical laboratory, Faculty of Health Sciences, Amoud   University, Somaliland ^bSchool of   postgraduate study and research ,  Amoud University, Borama,Somaliland. ^cDepartment of Mathematics, Faculty of Science, University of Lagos, Akoka, Yaba, Lagos, Nigeria
Abstract:
Background & Aims : Helicobacter pylori infection is a global public health problem, affecting over 50% of the population worldwide. Helicobacter pylori infection is recognized as the most common cause of chronic gastritis and is strongly linked to peptic ulcer disease and gastric cancer. Factors associated with H. pylori infections are nonsteroidal anti-inflammatory drugs, socioeconomic status, and household hygiene practices. Therefore, this study attempts to understand the association between the uses of non-steroidal anti-inflammatory drugs and Helicobacter pylori infection among patients attending private clinics in the Borama district, Somaliland. Methods: Correlation cross-sectional survey research design was conducted to assess the association between the uses of non-steroidal anti-inflammatory drugs and Helicobacter pylori infection among patients attending private clinics in the Borama district, Somaliland, and the period of the study was from October 2019 to August 2020. Data was extracted from 152 patients’ records, which included the gender, residence , marital status , age , level of education, and use of non-steroidal anti-inflammatory drugs. Descriptive statistics and chi-square tests were used to describe and report in figures and tables.. Results: The study indicates that the status of use of non-steroidal anti-inflammatory drugs among patients with Helicobacter pylori infection attending Borama private clinics was generally high. The study found that most (47.4%) of respondents indicated that they had always used non-steroidal anti-inflammatory drugs, 30.3% of the respondents sometimes used non-steroidal anti-inflammatory drugs, while 22.4% of the respondents indicated that they had not used non-steroidal anti-inflammatory drugs. Conclusions: This study indicates that the status of use of non-steroidal anti-inflammatory drugs among patients with helicobacter pylori infection attending Borama private clinics was generally high
Key Words: gender, residence , marital status , age , level of education, and association between the use of non-steroidal anti-inflammatory drugs and helicobacter pylori infection
[Download Full Paper] [Page 01-10]
================================================================================

2) Hexcel Corporation: Strategic Analysis 2024
Author Details: Dawar Jamal-CUNY School of Professional Studies Herbert Sherman, Long Island University – Brooklyn
Abstract:
Hexcel Corporation (NYSE: HXL) is a global leader in advanced composite materials and engineered products used primarily in commercial aerospace, space and defense, and industrial markets. Founded in 1948 and headquartered in Stamford, Connecticut, Hexcel has over 6,000 employees across 22 manufacturing and R&D facilities worldwide (Hexcel Corporation, 2024). Originally a supplier of lightweight honeycomb materials for military aircraft, the company has since evolved into a high-tech innovator specializing in carbon fiber, resin systems, and prepregs, which are materials critical to improving fuel efficiency, structural strength, and environmental sustainability
Approximately 65% of Hexcel’s total revenue is derived from the commercial aerospace sector, with Boeing and Airbus representing key clients (Hexcel Corporation, 2024). The remaining revenue stems from defense applications and industrial markets, including wind energy, automotive, marine, and sports equipment. According to its 2024 annual report, the company reported over $1.7 billion in revenue and $258 million in operating income, demonstrating solid financial performance and resilience in a competitive global market (Hexcel Corporation, 2024)
Hexcel’s competitive edge is rooted in its differentiation strategy, long-standing customer relationships, and proprietary technology. The company’s vertically integrated operations and global presence allow it to deliver consistent quality and innovation at scale. Moreover, Hexcel is aligned with global sustainability trends by focusing on lighter, stronger, and recyclable materials that reduce carbon emissions across industries (MarketWatch, 2023; IBISWorld, 2023)
Recent strategic initiatives include expansion into thermoplastic composite technologies, strengthening its position in high-rate manufacturing for next-generation aircraft (CompositesWorld, 2023). In 2023, Hexcel also announced new investments in its European facilities to increase capacity for aerospace prepreg production, as well as a supply agreement with GE Aviation to support long-term aerospace programs (Hexcel Corporation, 2024)
With a market capitalization exceeding $6 billion and a solid order backlog, Hexcel is well-positioned to capitalize on emerging opportunities in commercial aviation recovery, defense spending, and industrial innovation. Its blend of technology leadership, operational excellence, and sustainability focus makes it a formidable player in the global composites industry
Keywords:Hexcel Corporation, Strategic Analysis 2024
[Download Full Paper] [Page 11-28]
================================================================================